Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zai Lab Limited (ZLAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures related to its American Depositary Shares listed on the Nasdaq Global Market. Zai Lab is a research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on oncology, immunology, neuroscience, and infectious disease. Its SEC filings offer detailed information on financial performance, risk factors, capital structure, and key corporate agreements.
Through this page, users can review Zai Lab’s current reports on Form 8-K, which have covered topics such as quarterly financial results and the entry into a material definitive agreement for a renminbi-denominated revolving credit facility to support working capital needs in mainland China. These filings also describe how certain information, including earnings press releases furnished as exhibits, is treated for purposes of the Securities Exchange Act of 1934.
In addition to 8-Ks, investors can use this page as a starting point to locate Zai Lab’s annual and other periodic reports filed with the SEC, which discuss its dual-engine strategy, commercial portfolio in China, and global research and development programs. For a biopharmaceutical company like Zai Lab, these documents are important for understanding product revenue sources, R&D investment, licensing arrangements for medicines such as VYVGART, NUZYRA, ZEJULA, AUGTYRO, and COBENFY, and the financial implications of its pipeline.
Stock Titan enhances the raw filing data with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as new credit facilities, changes in operations, or significant clinical and commercial milestones referenced in the filings. Real-time updates from EDGAR, combined with organized access to forms including 8-K and other SEC documents, allow users to monitor ZLAB’s regulatory reporting and corporate actions efficiently.
ZLAB filed a Form 144 reporting a proposed sale of 853 American Depositary Shares.
The filing lists a proposed sale value of $17,442.57 and shows 307,140,690 shares on the record line with a 04/06/2026 date. The document also discloses recent transfers by Yajing Chen of 1,703 ADS on 03/13/2026 ($31,723.82) and 5,199 ADS on 04/02/2026 ($106,008.13), and a restricted stock vesting entry dated 04/02/2026.
Zai Lab Ltd Chairperson and CEO Du Ying reported routine equity compensation activity. On April 1–2, 2026, she exercised vested restricted share units, receiving 20,950 American Depositary Shares (ADSs), each representing ten ordinary shares. Of these, 5,576 ADSs were sold automatically at $20.39 per ADS to cover taxes due at vesting.
After these transactions, Du Ying directly holds 1,125,279 ADSs. Earlier, on March 4, 2026, performance conditions were confirmed for 25,579 performance-based share units, each representing a contingent right to one ADS. These PSUs vest in full on July 2, 2028, subject to continuous service.
Zai Lab Ltd Chief Financial Officer Chen Yajing reported several equity compensation transactions in American Depositary Shares (ADSs), each ADS representing ten ordinary shares. On April 1–2, 2026, Chen acquired a total of 17,758 ADSs through the vesting and settlement of Restricted Share Units (RSUs) at an exercise price of $0.00 per ADS.
On April 2, 2026, 5,199 ADSs were sold at $20.39 per ADS, and the footnotes state these ADSs were sold automatically to cover taxes upon RSU vesting. After these transactions, Chen directly held 32,558 ADSs.
Separately, on March 4, 2026, Chen was granted 11,924 performance-based share units (PSUs), each representing a contingent right to receive one ADS. The performance-based vesting conditions for these PSUs, tied to criteria measured between January 1, 2025 and December 31, 2025, were confirmed, and the PSUs vest in full on March 12, 2028, subject to continuous service.
Zai Lab Ltd officer Rafael Amado reported equity compensation activity and related tax sales in American Depositary Shares (ADSs), each representing ten ordinary shares. On April 1–2, 2026, he acquired a total of 24,914 ADSs through vesting and conversion of Restricted Share Units (RSUs) at a conversion price of $0.00 per ADS.
On April 2, 2026, 9,910 ADSs were sold at $20.39 per ADS, and the footnotes state these ADSs were sold automatically to cover taxes upon RSU vesting. After these transactions, he directly held 59,761 ADSs.
Separately, on March 4, 2026, Amado was credited with 14,905 performance-based share units (PSUs), representing a contingent right to receive the same number of ADSs. The performance-based vesting conditions for these PSUs, originally granted on March 12, 2025, were confirmed based on 2025 performance, and the PSUs will vest in full on March 12, 2028, subject to continuous service.
Zai Lab Ltd officer Joshua L. Smiley reported multiple equity compensation transactions involving American Depositary Shares (ADSs) and share units. On April 1, 2026, RSUs vested into 32,062 ADSs, and on April 2, 2026, additional RSUs vested into 7,145 ADSs, each RSU converting into one ADS at a price of $0.00 per unit.
On April 2, 2026, 9,614 ADSs were sold at $20.39 per ADS, with a footnote stating these shares were sold automatically to cover taxes upon RSU vesting. After these transactions, Smiley directly owned 120,619 ADSs. Separately, on March 4, 2026, he was credited with 17,887 performance-based share units, each representing a contingent right to receive one ADS, following satisfaction of 2025 performance criteria; these PSUs vest in full on March 12, 2028 subject to continuous service. RSUs referenced in the filing vest in equal annual installments over four years, with vested shares delivered in ADS form.
Zai Lab Ltd’s Chief Legal Officer, Edmondson Frazor Titus III, reported several equity compensation changes. He exercised restricted share units into a total of 22,290 American Depositary Shares (ADSs) at a conversion price of $0.00 per ADS-equivalent. Of these, 4,194 ADSs were automatically sold at $20.39 per ADS to cover taxes upon vesting, while the remainder were retained. He also received a grant of 11,924 performance-based share units tied to future ADS delivery. Following these transactions, he directly holds 24,590 ADSs.
ZLAB disclosure: a Form 144 notice reports resale activity in American Depositary Shares. The filing lists two completed sales by Rafael Amado — 10,000 ADS on 03/03/2026 for $173,800 and 2,957 ADS on 03/13/2026 for $55,083.59. The record also lists 9,910 ADS tied to restricted stock vesting dated 04/01/2026 under a compensation grant.
ZLAB filed a Form 144 reporting a proposed sale of 5,576 American Depositary Shares and recent dispositions by Ying Du.
The filing lists 5,576 ADS tied to Restricted Stock Vesting with an issuer designation dated 04/01/2026. It also records multiple past sales by Ying Du: four sales of 50,000 ADS on 03/04/2026, 03/05/2026, 03/06/2026, and 03/09/2026, and 1,067 ADS on 03/11/2026, each with reported gross proceeds shown alongside.
ZLAB filed a Form 144 reporting a proposed sale of 9,614 American Depositary Shares tied to restricted stock vesting on 04/01/2026. The notice lists Fidelity Brokerage Services LLC as the broker and shows an aggregate dollar amount of $196,030.42. The filing also discloses 1,966 ADS sold on 03/13/2026 as sales in the past three months.
ZLAB reporting person filed a Form 144 reporting an intended sale of 4,194 American Depositary Shares. The filing lists the 4,194 ADS as Restricted Stock Vesting with an effective date of 04/01/2026 and indicates the shares are connected to compensation.
The filing also discloses prior sales by Frazor T. Edmondson: 15,569 ADS sold on 03/05/2026 for $296,745.14, and 1,281 ADS sold on 03/13/2026 for $23,862.72.